Loading...
•
Dec 31, 2023
Mersana Q4 2023 Earnings Report
Mersana reported its Q4 2023 financial results and provided a business update.
Key Takeaways
Mersana Therapeutics reported the advancement of its clinical trials for XMT-1660 and XMT-2056, progress in collaborations with Johnson & Johnson and Merck KGaA, and provided an update on its financial results for the fourth quarter and full year ended December 31, 2023.
Continued to advance Phase 1 clinical trial of XMT-1660, with initial data expected in mid-2024.
Restarted Phase 1 clinical trial of XMT-2056 after the lifting of a clinical hold by the FDA.
Advanced collaborations with Johnson & Johnson and Merck KGaA.
Presented clinical data for discontinued NaPi2b ADC product candidates at ESGO 2024 Congress.
Forward Guidance
Mersana plans to share initial dose escalation and backfill cohort data for XMT-1660 in mid-2024 and advance dose escalation in the Phase 1 clinical trial of XMT-2056.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...